Podcasts about myeloid

ReferencesPNAS. 2011. May 24| vol. 108 | no. 21 .E118–E127 Discov Immunol. 2024 Nov 19;3(1):kyae016Cureus. 2025 Sep26;17(9):e93294Cell Reports Medicine 2022. Volume 3, Issue 3, 15 March 100543Discov Immunol. 2024 Nov 19;3(1):kyae016.Guerra, DJ. 2026 Unpublished LecturesMcQuinn,ParsonsKelly, Hillman, Dylan, Haggard.1968.Sweetheart of the Rodeo .lp .Byrdshttps://music.youtube.com/playlist?list=OLAK5uy_kejb97oJ9VJCssjIxpz2YeHK9htTy-wz0&si=XNJafnmA_B64KHcs

ReferencesGuerra, DJ.2026. Unpublished LecturesMcClean, D. 1971 American Piehttps://open.spotify.com/track/1fDsrQ23eTAVFElUMaf38X?si=05a7bcbf872c4220

ReferencesDiscov Immunol. 2024 Nov 19;3(1):kyae016Cell Reports2015 Volume 13, Issue 1p132-144October 06, Guerra. DJ.2026.Unpublished Lectures.Hayward/Pinder/Thomas/Edge.1969. To Our Children's Children Moody Blueshttps://music.youtube.com/playlist?list=OLAK5uy_nUbo_GZxI3GafKmIJazCD_XP1LSA5bRX4&si=sFMKnz_osf0rlmmu

ReferencesDiscov Immunol. 2024 Nov 19;3(1):kyae016Cell Metab. 2012 Jun 6;15(6):813-26. Dev Comp Immunol . 2020 Aug:109:103694. Guerra, DJ.2026. Unpublished LecturesMozart, WA. 1791. String Quintet in E-flat major, K. 614.https://music.youtube.com/watch?v=hEFu9iV0Zxw&si=xmWnzWorPG9Xtqzy

ReferencesGastroenterol Res Pract. 2025 Feb 26;2025:4950214Guerra, DJ. 2026. Unpublished LecturesStaines, B.1979 The Logging Songhttps://open.spotify.com/track/23NH1l9Gn2RmAtMYt9oLfr?si=88a409a32f364989

ReferencesFront Immunol. 2020 Jul 8;11:1024Neural Regen Res. 2019 Apr;14(4):595–596.Guerra, DJ. 2026. Unpublished LecturesLennon/McCartney. 1966 Good Day Sunshine. Beatleshttps://open.spotify.com/track/7HTH1ppjkkOe7RLoBDKXYJ?si=81b7d875d47a48ee

ReferencesFront Immunol. 2025 Dec 3;16:1712452.Nat Commun. 2024 Nov 12;15:9803. Guerra, DJ.2026.Unpublished LecturesMiller, S. 1970. Steven Miller Band Vhttps://music.youtube.com/playlist?list=OLAK5uy_mMurbyyiMLz7bvTAJmI_j8sCs_e-NbvAM&si=0i95A7H0jAkW7AU2

ReferencesNature Communications2=18. Vol. 9,Article number: 1228 PLoS One. 2024 Jul 5;19(7):e0304997Guerra, 2026 Unpublished LecturesSquire et al. 1971. Yes. Heart of the Sunrise Yessopngshttps://open.spotify.com/track/3vwjrVDFKelpfuD6yO1oW4?si=821bc04addaf46dd

ReferencesJCI Insight. 2018 Sep 6;3(17):e121630Signal Transduction and Targeted Therapy2022.. 7, : 304 Arthritis Res Ther.2021; 23: 19.MDPI Genes 2021, 12(9), 1313; https://doi.org/10.3390/genes12091313Guerra, DJ.2026. Unpublished LecturesLennon/McCartney. 1965. Wait Rubber Soul Beatleshttps://music.youtube.com/watch?v=qJngWval8Bc&si=9ZTkMl5YuJ870EJ4Lennon/McCartney.1968. Long Long Long White Album. Beatles.https://music.youtube.com/watch?v=e9vUCdfwlgw&si=p-8M8n6bgUurCuq8

References Nat Struct Mol Biol . 2006 Dec;13(12):1097-101Open Biol. 2013 Oct;3(10):130144Arthritis Res Ther.2021; 23: 19.European Review for Medical and Pharmacological Sciences 2021; 25: 1425-1435Frontiers in Immunology 2024 09 January DOI 10.3389/fimmu.2023.132280Guerra, DJ. 2026.Unpublished Lectures.Teleman, G P 1716. Concerto in D. TWV51 https://music.youtube.com/watch?v=F5J80v3ACbo&si=oiJxKkpbnLhiZ833Hunter/Garcia.1973. Stella Blue. Grateful Dead.https://music.youtube.com/watch?v=VKsWDyvWaL4&si=Jul71w1djWl2WTIIp. 1716. D1 TWV51.

ReferencesFrontiers in Immunology 2014. November 21(578):1Clin Epigenetics. 2017; 9: 94. Cancer Cell International 2020. September 20(1):429Guerra, DJ.2026. Unpublished Lectures.Vinsom/Chapman/Burnett. 1930. Sitting On Top of the World Creamhttps://open.spotify.com/track/0aY5bJ4jRHiOd8eCMWmcy8?si=b3c7f2090c6e441cJagger/Richards.1965.Satisfaction Rolling Stoneshttps://open.spotify.com/track/2PzU4IB8Dr6mxV3lHuaG34?si=6b244c676bf1454eLennon/McCartney. 1968 Helter Skelterhttps://open.spotify.com/track/0Bs0hUYxz7REyIHH7tRhL2?si=f345fea1161a4f27Paige/ Plant 1971. Rock and Roll Led Zepplinhttps://open.spotify.com/track/4PRGxHpCpF2yoOHYKQIEwD?si=3203893185c24bee

ReferencesAtherosclerosis .2012 Mar;221(1):2-11.Antiox and Redox Sig. 2018. March 30(6):813-856Experimental Immunol. 2018.v87. issue 4:e12648Scand J Immunol. 2018 Apr;87(4):e12648Front. Immunol. Sec. Cancer Immunity and Immunotherapy 2025. vol16 05 February Guerra,DJ.2026.Unpublished Lectures.Dvorak. A. 1894. American Suite in A Major. op.98https://music.youtube.com/watch?v=yi37I6w46FM&si=hhBZx2_TqEu9Txmn

References Sci Signal. 2017 Jul 25;10(489)EMBO Rep. 2017 Mar 7;18(4):645-657`Guerra, DJ. 2026. Unpublished LecturesHunter/Garcia, et al.1970. American Beauty lp. Grateful Dead.https://music.youtube.com/playlist?list=OLAK5uy_nc3dHmM6xdsySO1SSxYLYzlm82rVZ1pfM&si=2xOrRK6QpYFeI8Is

TWiM explains the connection between inflammation caused by microbial glycogen in the gut and amyotrophic lateral sclerosis, and how disruption of cysteine metabolism leads to synthetic lethality and in vivo fitness impairment in Acinetobacter baumannii. Become a patron of TWiM. Links for this episode: Myeloid cell gene prevents inflammatory response to microbial glycogen (Cell Rep) Cysteine metabolism and fitness impairment in Acinetobacter baumannii (mBio) Music used on TWiM is composed and performed by Ronald Jenkees and used with permission. Send your microbiology questions and comments to twim@microbe.tv

ReferencesBiochimica et Biophysica Acta (BBA) 2026 - Molecular Basis of Disease February168069 Volume 1872, Issue 2Comput Math Methods Med. 2012 Sep 16; 2012:173521Front. Immunol.2026. 15 April Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune DisordersVolume 17 - 202Guerra, DJ. 2026. Unpublished LecturesHunter/Garcia.1973. US Blues Grateful Deadhttps://music.youtube.com/watch?v=-IBk5xk5Pec&si=yMHTzyV2p8xsIZly

ReferencesNeuroendocrinology. 2000 Mar;71(3):187-95J Immunol.2014 Jan 3;192(3):979–984.Molecular and Cellular Endocrinology 2018.Volume 472, 5 September: 40-49Front. Immunol., 2023. 16 March Sec. T Cell Biology.Volume 14 -Guerra, DJ. 2026. Unpublished Lectures.Emerson/Lake/Palmer. 1972. Trilogy lp. fullhttps://music.youtube.com/playlist?list=OLAK5uy_m-KrYKLiBdrOau11bsTte7M4qSR0en7VI&si=DwpdwN0nR_IGNsK1

In this first deep dive, Christopher Cogle explores the evolving landscape of acute myeloid leukaemia (AML). He discusses the challenge of translating research into real-world outcomes, emerging immunotherapies, precision diagnostics, and how innovations such as the Acute Leukemia Methylome Atlas may reshape AML management in the future.  Timestamps:  00:55 – Research Gaps  03:50 – Biologics  05:46 – AML Atlas  09:15 – Immunotherapy 

OsteoBites welcomes Caroline Maloney, MD, PhD, from the Medical College of Wisconsin, who will discuss her research on surgery-accelerated metastasis and developing perioperative therapies.Pulmonary metastasis remains the major cause of death in osteosarcoma. The timing of metastatic relapse defines clinically meaningful subgroups in osteosarcoma with patients who relapse within 6–12 months of surgical removal of their primary tumor having markedly worse survival (10-20%) than those who relapse after completion of therapy (40-50%). While surgical removal of the primary tumor is a fundamental component of the clinical care of solid tumors, surgery induces transient but profound changes in immune and inflammatory responses that can paradoxically accelerate the growth of metastatic disease. Dr. Maloney has demonstrated that surgical removal of the primary tumor accelerates the growth of pre-existing pulmonary metastatic disease and promotes expansion of M2‐like macrophages in the lung microenvironment. Strikingly, short term perioperative treatment with a RIPK2 inhibitor blocks this effect and reprograms macrophages toward an M1-like phenotype, implicating the NOD2–RIPK2 innate immune pathway as a key mediator of post‐surgical immune reprogramming. In contrast, the NOD2 agonist Mifamurtide has shown clinical efficacy when administered as adjuvant therapy to metastatic osteosarcoma patients after primary tumor resection. This data suggests that NOD/RIPK2 signaling may exert context-dependent effects, promoting either pro- or anti-tumor myeloid responses depending on the timing of activation relative to surgery. Understanding how surgical tumor removal alters systemic innate immunity and how RIPK2 signaling orchestrates these responses could identify new strategies to prevent early pulmonary relapse after surgery.

In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.1. PARADIGM Trial (Plenary Session, Abstract 6)Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.https://doi.org/10.1182/blood-2025-6ClinicalTrials.gov: NCT048017972. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.ClinicalTrials.gov: NCT055205673. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911ClinicalTrials.gov: NCT041404874. PRISM-AML Score (Abstract 453)Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.Interactive Calculator: https://prism-aml.com5. Additional Studies Referenced in Discussion•       VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)•       VERONA Trial: Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed as a negative study)•       4-Gene Classifier (mPRS): Bataller A, et al. Prognostic risk signature in patients with AML treated with HMA and venetoclax. Blood Adv 2024;8(4):927–935. https://doi.org/10.1182/bloodadvances.2023011757•       LACEWING Trial: Azacitidine plus gilteritinib vs. azacitidine plus placebo in FLT3-mutated AML (discussed as a negative study) 

In this special two-part episode of Hema Now, Catherine Glass takes you through the incredible line-up of guests from 2025. From congress presidents to pioneering clinicians and researchers, this podcast has spotlighted some of the leading voices in the field of Hematology. Explore their most impactful insights and hear how recent advances are shaping clinical practice and future research. Timestamps:       00:00 – Introduction  01:04 – Advances in lymphoma and transplant  06:15 – Epigenetics in leukaemia  08:46 – Multiple myeloma care today  11:49 – Metabolism's role in leukaemia  14:51 – Myeloid malignancy biology and treatment  16:50 – New therapies for chronic lymphocytic leukaemia  21:44 – Outro 

The former St. Jude patient treated for cancer and sickle cell disease says her health journey helped her become determined, strong and hopeful.

Hugues de ThéCollège de FranceOncologie cellulaire et moléculaireAnnée 2024-2025Colloque - Oxidative Stress in Cancer - Raphaël Itzykson : Targeting Cystine Import in Acute Myeloid LeukemiasRaphaël ItzyksonUniversité Paris Cité, Assistance Publique – Hôpitaux de Paris

In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology's hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn't just helpful—it's lifesaving.  

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Drs. Sanam Loghavi and Amer Zeidan delve into the history behind the recent classification split between the World Health Organization (WHO) and the International Consensus Classification (ICC) for myeloid and lymphoid malignancies, and how a few years of minor disagreement have culminated in a unified system. They explore the critical differences in how myeloid and lymphoid neoplasms are now categorized, what this alignment means for pathologists, oncologists, regulators, and patients, when the new classification will take effect, and how it is expected to influence research, diagnosis, and clinical care. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Daniel Getts, the CEO and Founder of Myeloid Therapeutics is focused on the role of myeloid cells in the immune response to solid tumors. These cells are the first responders in the immune system and play a crucial role in bridging the innate and adaptive immune response. The Myeloid Therapeutics' mRNA technology activates myeloid cells in tumors, making the tumor microenvironment hot and attracting other immune cells to fight the cancer. Daniel explains, "The ability to harness our immune systems has revolutionized how we treat cancer. Unfortunately, we still have a long way to go, and if you think about some of the worst of the worst cancers, such as pancreatic cancer, liver cancer, and so on, immunotherapy has still not gotten us to a place where we can solve this. It's our mission at Myeloid Therapeutics to overcome these challenges. We've uncovered a lot of really interesting things about these cancers in the last 20 years, and we've been harnessing that knowledge."  "Myeloid cells are at the heart of the immune system. They're the first responders. So, if you have an infection or bump your knee, these cells are immediately called to the site to wall off and prevent any more damage. However, they also serve as the bridge to adaptive immunity, the T cells and the B cells, which are also important for integrating an immune response. In the context of COVID vaccines, we talk about antibodies and T cells, it's the myeloid cells that are essential. In the context of what we've been learning, immunotherapy, up until recently, had been very focused on T cells and how to short-circuit the whole system just by using or activating those cells to kill cancer. And what we're starting to learn is to harness the full capability of our own immune systems, you've got to go back to the start. You've got to harness the myeloid compartment so you can orchestrate all immune elements to kill cancer." #MyeloidTherapeutics #MyeloidCells #ImmuneSystem #SolidTumors #Cancer #ImmuneResponse #Oncology #TumorMicroenvironment myeloidtx.com Download the transcript here

Daniel Getts, the CEO and Founder of Myeloid Therapeutics, is focused on the role of myeloid cells in the immune response to solid tumors. These cells are the first responders in the immune system and play a crucial role in bridging the innate and adaptive immune response. The Myeloid Therapeutics' mRNA technology activates myeloid cells in tumors, making the tumor microenvironment hot and attracting other immune cells to fight the cancer. Daniel explains, "The ability to harness our immune systems has revolutionized how we treat cancer. Unfortunately, we still have a long way to go, and if you think about some of the worst of the worst cancers, such as pancreatic cancer, liver cancer, and so on, immunotherapy has still not gotten us to a place where we can solve this. It's our mission at Myeloid Therapeutics to overcome these challenges. We've uncovered a lot of really interesting things about these cancers in the last 20 years, and we've been harnessing that knowledge."  "Myeloid cells are at the heart of the immune system. They're the first responders. So, if you have an infection or bump your knee, these cells are immediately called to the site to wall off and prevent any more damage. However, they also serve as the bridge to adaptive immunity, the T cells and the B cells, which are also important for integrating an immune response. In the context of COVID vaccines, we talk about antibodies and T cells, it's the myeloid cells that are essential. In the context of what we've been learning, immunotherapy, up until recently, had been very focused on T cells and how to short-circuit the whole system just by using or activating those cells to kill cancer. And what we're starting to learn is to harness the full capability of our own immune systems, you've got to go back to the start. You've got to harness the myeloid compartment so you can orchestrate all immune elements to kill cancer." #MyeloidTherapeutics #MyeloidCells #ImmuneSystem #SolidTumors #Cancer #ImmuneResponse #Oncology #TumorMicroenvironment myeloidtx.com Listen to the podcast here

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/FLAG-GO vs FLAG-IDA https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine CPX-351: Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.htmlAbstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.htmlMenin Inhibitors Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.htmlAbstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.htmlAbstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.htmlAbstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html FLT3 inhibitors Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html MDS Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html ATRA in MDS:  https://ash.confex.com/ash/2024/webprogram/Paper200433.html  

This week Jonathan is joined by Joshua Zeidner, Associate Professor of Medicine, University of North Carolina School of Medicine, USA. Together, they discuss findings from recent research and treatment options for acute myeloid leukaemia and myelodysplastic syndrome. Timestamps:     (00:00)- Introduction    (01:57)- Joshua's love for the New York Giants  (04:28)- Treatment outcomes in IDH1 and IDH2-mutated acute myeloid leukaemia (AML)  (08:05)- Safety and efficacy of new agents in AML  (17:00)- Treatments for patients with AML with a TP53 mutation  (22:02)- Reliance on transfusion in myelodysplastic syndrome (MDS)  (25:44)- The time from research lab to bedside in drugs to treat AML and MDS  (30:50)- Joshua's three wishes for healthcare   (35:13)- Outro   

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the checkpoint inhibitor combination: nivolumab + ipilimumab. At the conference, Oncology Times reporter Peter Goodwin caught up with lead author of the study, Bart Neyns, MD, PhD, Head of Medical Oncology at the Vrije Universiteit Brussel in the University Hospital Brussels Faculty of Medicine & Pharmacy in Belgium.

Ximena Jordan-Bruno, MD, University of Pennsylvania, Philadelphia, PA Recorded on June 4, 2024 Ximena Jordan-Bruno, MD Assistant Professor, Division of Hematology/Oncology University of Pennsylvania Philadelphia, PA Join us for this fascinating episode, where Dr. Ximena Jordan-Bruno from the University of Pennsylvania explores hereditary myeloid and hematologic disorders, covering their classifications, mutations, and related germline predisposition syndromes. Learn about key clinical features, diagnostic approaches, the role of genetic counseling, and future research directions. Tune in today for valuable updates to enhance your understanding and practice!

Dr. Kipp Weiskopf is a Valhalla Fellow at the Whitehead Institute. His research focuses on unlocking the therapeutic potential of macrophages for the benefit of cancer patients. He talks about the role of macrophages in the tumor environment and how targeting the CD47/SIRPα axis can induce phagocytosis of cancer cells. He also discusses starting spin-off companies to advance cancer therapies.

This podcast follows the case of a 58 year old man who presented to the haematology department at Flinders Medical Centre with intravascular coagulation and leukocytosis. He was diagnosed with acute myeloid leukaemia and treated on standard cytarabine and daunorubicin combination therapy. Nine days after initiation, the patient developed painless diplopia and ptosis, and the story is picked up with a referral to the neurology department. GuestsAssociate Professor Stephen Bacchi (Lyell McEwin Hospital; University of Adelaide)Dr James Triplett FRACP (Flinders Medical Centre, consultant neurologist) ProductionProduced by Stephen Bacchi and Mic Cavazzini. Music licenced from Epidemic Sound includes ‘Rockin' for Decades' by Blue Texas and ‘Brighton Breakdown' by BDBs. Image created and copyrighted by RACP. Editorial feedback kindly provided by RACP physicians Aidan Tan and Brandon Stretton.Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record listening and reading as a prefilled learning activity.Key Reference and Learning Points (Spoiler Alert)********Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis [J Neuroimmunol. 2023]  (1) Chemotherapy can have neurological complications, including chemotherapy induced peripheral neuropathy (e.g., oxaliplatin).(2) A third (oculomotor) cranial nerve palsy has multiple possible causes, which can be divided into painful vs painless causes, and compressive (classically with pupillary involvement) vs non-compressive (can spare pupil, as with microvascular insult) causes.(3) Conduction block is shown by a significant reduction in compound muscle action potential, between proximal and distal stimulation, the criteria for which varies by nerve.(4) Ascertaining whether conduction block occurs at compressible vs non-compressible sites can be a useful distinguishing feature for the various possible causes e.g. including compression, demyelination, and ischaemia, and (5) Mononeuritis multiplex, while classically associated with a vasculitic neuropathy, has a number of causes, including leukaemia. This is the very rare condition known as neuroleukemiosis.

BUFFALO, NY- July 19, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.” In this new editorial, researcher Hirotaka Matsui from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University discusses myeloid neoplasms. Until the early 2000s, myeloid neoplasms attributable to genetic backgrounds were considered exceedingly rare, with notable exceptions limited to those arising as components of systemic syndromes such as Fanconi anemia and Li-Fraumeni syndrome. Historically, no hematopoietic-specific tumor syndromes had been identified until 1999, when RUNX1 was implicated as the causative gene for familial platelet disorder with a predisposition to acute myeloid leukemia (AML). Subsequently, in 2004, CEBPA was recognized as another critical gene responsible for inherited AML. The subsequent advent and widespread application of comprehensive genetic analysis facilitated the identification of germline pathogenic variants in genes such as ANKRD26, ETV6, and GATA2 among patients with myeloid neoplasms that developed against a background of inherited thrombocytopenia or systemic disorders. It is now established that genetic predisposition is present in approximately 10% of myeloid neoplasms, underscoring the fact that myeloid neoplasms with a genetic background are by no means exceptional. “Among these, myeloid neoplasms caused by DDX41 variants are particularly noteworthy due to their distinct disease phenotype and pathogenesis [2].” DOI - https://doi.org/10.18632/oncotarget.28603 Correspondence to - Hirotaka Matsui - hmatsui@ncc.go.jp Video short - https://www.youtube.com/watch?v=AQXIdS1amhM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28603 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, acute myeloid leukemia, DDX41, myelodysplastic neoplasms, myeloid neoplasms with germline predisposition, R-loop About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,... The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed:1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis https://ash.confex.com/ash/2023/webprogram/Paper173509.html 2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study https://ash.confex.com/ash/2023/webprogram/Paper179141.html 3. Venetoclax + Decitabine vs 7+3 in AML https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax 4. FILO study: Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. https://ash.confex.com/ash/2023/webprogram/Paper185437.html  5. AUGMENT-101: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results https://ash.confex.com/ash/2023/webprogram/Paper172422.html 6. VEN+HMA in HR MDS: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study https://ash.confex.com/ash/2020/webprogram/Paper139492.html

In this week's episode we'll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI therapy.

If you're looking to improve your circulation / blood flow and athletic performance or simply combat increased vascular permeability (which can create edema and, therefore, hypoxia) due to the damaging effects of hyperglycemia, inflammation, toxins, etc..., then this episode is a MUST-listen! We're delving into the intricacies of the vesugen bioregulator peptide – so stay tuned for some pretty intriguing research! Topics: 1. Introduction to the Episode - Previous background interest in vesugen: Lyme and Mold / CIRS issues - Introduction to bioregulator peptide vesugen - Effects on blood vessels, circulation, hypoxia, and athletic performance 2. Quick Overview of CIRS and the Circulatory System - Damage to the endothelial blood vessel wall due to high MMP-9 levels - Hemolysins released by MARCoNS - Narrowed capillaries and induced hypoxia - Interest in vesugen 3. Blood Cell Formation - Hematopoiesis - Process and origin in the bone marrow - Characteristics of multipotent hematopoietic stem cells (HSCs) - Regulation of HSC self-renewal vs. differentiation - Myeloid and Lymphoid Progenitors - Differentiated blood cells from each progenitor type - Pathway: Myeloid progenitor to erythrocyte - Role of Erythropoietin (EPO) 4. Maturation Process of Erythrocytes - Ejection of nucleus and organelles - Hemoglobin acquisition - Biconcave shape for optimal gas exchange - Transition to the bloodstream via sinusoids 5. Vascular Wall Anatomy and Dysfunction - Overview of vascular wall layers: Tunica intima, tunica media, and tunica externa - Detailed understanding of endothelial cell functions - Barrier function and vascular permeability - Vascular tone and blood flow regulation - Inflammation and the role in immune response - Angiogenesis and its significance 6. Bioregulator Peptide Vesugen - Definition and unique characteristics - Composition: Lysine, Glutamine, and Asparagine - Mechanism of action: Promotion of endothelial cell proliferation 7. Benefits and Potential of Vesugen - Restoration of endothelial function - Role in injury and endothelial dysfunction scenarios: edema, hypoxia, etc... - Protective effect on the blood-brain barrier - Impact on nitric oxide production and athletic performance, hair growth, skin health Thanks so much for tuning in! Pre-Order Chloe's Book "⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠" and email thesynthesisofwellness@gmail.com a screenshot of the order confirmation to enter the GIVEAWAY! If you liked this episode, please leave a rating and review or share it to your stories over on Instagram. If you tag @synthesisofwellness, Chloe would love to personally thank you for listening! Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Chloe on TikTok @chloe_c_porter Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ to purchase products, subscribe to our mailing list, and more! Or visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠linktr.ee/synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠ to see all of Chloe's links, schedule a BioPhotonic Scanner consult with Chloe, or support the show! Thanks again for tuning in! --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support

In this week's episode, we'll discuss pembrolizumab after autologous stem cell transplantation in patients with peripheral T-cell lymphoma. Newly reported phase 2 study results show that blocking PD-1 with pembrolizumab had a favorable safety profile and demonstrated promising activity, supporting further confirmatory studies in this setting; germline genetic predisposition to myeloid neoplasms in patients with hypoplastic bone marrow. Researchers report mutations that are significantly associated with cytopenias in adulthood in these patients. And pathogenic or likely pathogenic variants were linked to severe cytopenias and advanced myeloid malignancies; and finally, if monocytes and their descendants are less plastic than previously thought. Investigators have identified four functionally specialized monocyte subsets that derive from specific myeloid progenitor lineages. They show that the fate of these monocyte subsets is epigenetically scripted, with little flexibility after differentiation begins, even under conditions of stress.

In this week's episode, we'll learn more about ventricular arrhythmias in sickle cell anemia, discuss the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders, and uncover the role of the bone marrow microenvironment as a driver of myeloid disorders.

In this week's episode we'll report on the findings from a 5-year follow-up study of axicabtagene ciloleucel in refractory large B-cell lymphoma, discuss the role of C1 inhibitor deficiency in coagulation and venous thrombosis, and learn how chemotherapy signatures can be used to track the evolution of therapy-related myeloid neoplasms.

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso discuss post-PARP myeloid neoplasms. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) under the mentorship of Professor Nicoletta Colombo and has now started his research fellowship period at Mayo Clinic (Rochester) under the supervision of Professor William Cliby. His main interest areas are gynecologic oncology, personalized oncology, and clinical research. Highlights: - Myeloid neoplasms post PARPi in patients with ovarian cancer are gradually emerging as life-threatening late toxicities and should not be underestimated. - The first two years of PARPi exposure are the critical window of onset and persistent cytopenia has been recognized as an early warning sign. - Active surveillance, differential diagnosis, and prompt hematological referral are crucial. - PARPi are recommended in the first line also to improve the risk-benefit ratio. - PARPi should be used cautiously in patients with a higher baseline risk and/or those who are less likely to have a significant benefit.

1.     Phase III ASAP trialhttps://ash.confex.com/ash/2022/webprogram/Paper159962.html  2.     Phase III Dauno-Double Trialhttps://ash.confex.com/ash/2022/webprogram/Paper157126.html  3.     Reduced venetoclax exposure: https://ash.confex.com/ash/2022/webprogram/Paper165464.html  4.    Menin Inhibitors in AML https://ash.confex.com/ash/2022/webprogram/Paper164849.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper167412.html  5.    Imetelstat in MDS: IMerge Phase 2https://ash.confex.com/ash/2022/webprogram/Paper169050.html  6.    MOMENTUM: Momelotinibhttps://ash.confex.com/ash/2022/webprogram/Paper162783.htmlHow I manage anemia related to myelofibrosis and its treatment regimens https://link.springer.com/article/10.1007/s00277-023-05126-4

Hear about a new treatment that may be able to reverse hearing loss, how new solar energy storage technology could eventually power our phones, and the surprisingly grand history of chickens.Reversing hearing loss. “Reversing hearing loss with regenerative therapy” by Zach Winnhttps://news.mit.edu/2022/frequency-therapeutics-hearing-regeneration-0329“What are Progenitor Cells? Exploring Neural, Myeloid and Hematopoietic Progenitor Cells” by Nicole Gleichmannhttps://www.technologynetworks.com/cell-science/articles/what-are-progenitor-cells-exploring-neural-myeloid-and-hematopoietic-progenitor-cells-329519“Quick Statistics About Hearing” by the National Institute on Deafness and Other Communication Disordershttps://www.nidcd.nih.gov/health/statistics/quick-statistics-hearing“PCA Approach” and “About Hearing Loss” by Frequency Therapeuticshttps://www.frequencytx.com/science/pca-approach/https://www.frequencytx.com/hearing-loss/about-hearing-loss/“FX-322 in Adults With Acquired Sensorineural Hearing Loss” by Frequency Therapeutics Clinical Trialhttps://clinicaltrials.gov/ct2/show/NCT05086276Phone charger, but make it the sun.“Converting solar energy to electricity on demand” by Chalmers University of Technologyhttps://techxplore.com/news/2022-04-solar-energy-electricity-demand.html“For a Better Future” by The MOST Solar Projecthttps://mostsolarproject.eu/“Molecular solar thermal (MOST) energy storage and release system” by Kasper Moth-Poulsen, et al.https://pubs.rsc.org/en/content/articlelanding/2012/ee/c2ee22426g“Solar Energy: Benefits and Drawbacks” by Matthew Johnstonhttps://www.investopedia.com/articles/investing/053015/pros-and-cons-solar-energy.aspChicken breeding.“The biocultural origins and dispersal of domestic chickens” by Joris Peters, Ophélie Lebrasseur, Evan K. Irving-Pease, Ptolemaios Dimitrios Paxinos, Julia Best, Riley Smallman, Cécile Callou, Armelle Gardeisen, Simon Trixl, Laurent Frantz, Naomi Sykes, Dorian Q. Fuller, and Greger Larson.https://www.pnas.org/doi/full/10.1073/pnas.2121978119“A new origin story for domesticated chickens starts in rice fields 3,500 years ago” by Bruce Bower.https://www.sciencenews.org/article/chicken-domestication-bones-origin-asia-rice-fields-exotic-animals“Redefining the timing and circumstances of the chicken's introduction to Europe and north-west Africa” by Julia Best, Sean Doherty, Ian Armit, Zlatozar Boev, Lindsey Büster, Barry Cunliffe, Alison Foster, Ben Frimet, Sheila Hamilton-Dyer, Tom Higham, Ophélie Lebrasseur, Holly Miller, Joris Peters, Michaël Seigle, Caroline Skelton, Rob Symmons, Richard Thomas, Angela Trentacoste, Mark Maltby, Greger Larson, and Naomi Sykeshttps://www.cambridge.org/core/journals/antiquity/article/redefining-the-timing-and-circumstances-of-the-chickens-introduction-to-europe-and-northwest-africa/0797DAA570D51D988B0514C37C2EC534Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/healing-hearing-hairs-sun-phones-chicken-gods